Информация предназначена только для профессионалов в области здравоохранения.
Вы можете зайти как пользователь социальных сетей
1ФГБУ Московский НИИ психиатрии Минздравсоцразвития РФ 2Психоневрологический диспансер №21, Москва 3Психоневрологический диспансер №1, Москва
Список исп. литературыСкрыть список 1. Вовин Р. Я. Динамика ремиссий при шизофрении и их рациональная психофармакотерапия. Профилактическая и противорецидивная терапия психических заболеваний. Л., 1986; с. 5–16. 2. Зеневич Г.В. Ремиссии при шизофрении. Л.: Медицина, 1964. 3. Коцюбинский А.П., Скорик А.И., Аксенова И.О. и др. Шизофрения: уязвимость–стресс–диатез–заболевание. СПб.: Гиппократ Плюс, 2004; с. 88–109. 4. Международная классификация болезней (10-й пересмотр). Классификация психических и поведенческих расстройств. Клинические описания и указания по диагностике. ВОЗ, Россия. СПб.: Оверлайд, 1994. 5. Мелехов Д.Е. Клинические основы прогноза трудоспособности при шизофрении. М.: Медгиз, 1963. 6. Морозов В.М. Ремиссии при шизофрении и вопросы трудовой экспертизы и трудоустройства. Журн. неврол. и психиатр. им. С.С.Корсакова. 1953; 10: 770–4. 7. Морозов В.М., Тарасов Ю.К. Некоторые типы спонтанной ремиссии при шизофрении. Журн. неврол. и психиатр. им. С.С.Корсакова. 1951; 4: 44–7. 8. Мосолов С.Н. Шкалы психометрической оценки шизофрении и концепция позитивных и негативных расстройств. М.: Новый цвет, 2001. 9. Мосолов С.Н., Потапов А.В., Дедюрина Ю.М. и др. Валидизация международных критериев на популяции амбулаторных больных. Журн. неврол. и психиатр. им. С.С.Корсакова. 2010; 110 (5): 71–5. 10. Свердлов Л.С. Клинико-психопатологический и клинико-психологический анализ процесса формирования терапевтических ремиссий при острых шизофренических приступах. Биологическая терапия в системе реабилитации психически больных. Л., 1980; с. 48–60. 11. Смулевич А.Б., Андрющенко А.В., Бескова Д.А. Проблема ремиссий при шизофрении: клинико-эпидемиологическое исследование. Журн. неврол. и психиатр. им. С.С.Корсакова. 2007; 5: 4–15. 12. American Psychiatric Association: Diagnostic and statistical manual of mental disorders. 4th ed. Text rev. Washington DC: American Psychiatric Association 1994. 13. Andreasen NC, Carpenter WT Jr, Kane JM et al. Remission in schizophrenia: proposed criteria and rational for consensus. Am J Psychiat 2005; 162: 441–9. 14. Buckley PF, Harvey PD, Bowie CR, Loebel A. The relationship between symptomatic remission and neuropsychological improvement in schizophrenia patients switched to treatment with ziprasidone. Schizophr Res 2007; 94: 99–106. 15. De Hert M, van Winkel R, Wampers M et al. Remission criteria for schizophrenia: evaluation in a large naturalistic cohort. Schizophr Res 2007; 92: 68–73. 16. Docherty JP, Bossie CA, Lachaux B et al. Patient-based and clinician-based support for the remission criteria in schizophrenia. Int Clin Psychopharmacol 2007; 22: 51–5. 17. Eberhard J, Levander S, Lindström E. Remission in schizophrenia: analysis in a naturalistic setting. Compr Psychiat 2009; 50: 200–8. 18. Emsley R, Chiliza B, Asmal L, Lehloenya K. The concepts of remission and recovery in schizophrenia. Curr Opin Psychiat 2011; 24: 114–21. 19. EUFAMI. Remission in schizophrenia – related survey 2012. 20. Gorwood P, Peusekens J. On behalf of the EGOFORS initiative (European Group On Functional Outcomes, Remission in Schizophrenia). Setting new standards in schizophrenia outcomes: Symptomatic remission 3 years before vs after the andreasen criteria. Eur Psychiat 2011. 21. Haro JM, Novick D, Suarez D et al. Remission and relapse in the outpatient care of schizophrenia – 3-year results from the Schizophrenia Outpatients Health Outcomes Study. J Clin Psychopharmacol 2006; 26: 571–8. 22. Helldin L, Kane JM, Karilampi U et al. Remission and cognitive ability in a cohort of patients with schizophrenia. J Psychiat Res 2006; 40: 738–45. 23. Kane JM, Crandall DT, Marcus RN et al. Symptomatic remission in schizophrenia patients treated with aripiprazole or haloperidol for up to 52 weeks. Schizophr Res 2007; 95: 143–50. 24. Kay SR, Fizbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261. 25. Kurihara T, Kato M, Reverger R, Tirta IG. Remission in schizophrenia: a community-based 6-year follow-up study in Bali. Psychiat Clin Neurosci 2011; 65: 476–82. 26. Lambert M, Karow A, Leucht S et al. Remission in schizophrenia: alidity, frequency, predictors, and patients’ perspective 5 years later. Dialogues Clin Neurosci 2010; 12: 393–407. 27. Lambert M, Schimmelmann BG, Naber D et al. Prediction of remission as a combination of symptomatic remission and adequate subjective well-being in 2960 patients with schizophrenia. J Clin Psychiat 2006; 67: 1690–7. 28. Lasser RA, Bossie CA, Gharabawi GM, Kane JM. Remission in schizophrenia: results from a 1-year study of long-acting risperidone injection. Schizophr Res 2005; 77: 215–27. 29. Leucht S, Beitinger R, Kissling W. On the concept of remission in schizophrenia. Psychopharmacol 2007; 194: 453–61. 30. Levine SZ, Rabinowitz J, Ascher-Svanum H et al. Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: evidence from the CATIE study. Schizophr Res 2011; 133: 42–6. 31. Li CT, Su TP, Chou YH et al. Symptomatic resolution among Chinese patients with schizophrenia and associated factors. J Formos Med Assoc 2010; 109: 378–88. 32. Liberman RP, Kopelowicz A, Venture J, Gutkind D. Operational criteria and factors related to recovery from schizophrenia. Int Rev Psychiat 2002; 14: 256–72. 33. Liddle PF. The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy. Brit J Psychiat 1987; 151 (5): 145–51. 34. Morosini PL, Magliano L, Brambilla L et al. Development, reliability and acceptability of a new version of the DSM-IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social functioning. Acta Psychiat Scand 2000; 101: 323–9. 35. Mosolov SN, Potapov AV, Ushakov VV. Remission in schizophrenia: results of cross-sectional with 6-month follow-up period and 1-year observational therapeutic studies in an out patients population. Ann Gen Psychiat 2012; 11: 1. 36. San L, Ciudad A, Alvaez E et al. Symptomatic remission and social/vocational functioning in outpatients with schizophrenia: prevalence and associations in a cross-sectional study. Eur Psychiat 2007; 22: 490–8. 37. Sheehan DV, Lecrubier Y, Sheehan KH et al. The mini-international neuropsychiatric interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiat 1998; 59: 22–3. 38. Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiat Scand 1970; 212 (1): 11–9. 39. Van Os J, Drukker M, Campo J et al. Validation of remission criteria for schizophrenia. Am J Psychiat 2006; 163: 2000–2. 40. Weiden P, Rapkin B, Mott T et al. Rating of medication influences (ROMI) scale in schizophrenia. Schizophr Bull 1994; 20 (2): 297–310. 41. Wobrock T, Köhler J, Klein P, Falkai P. Achieving symptomatic remission in outpatients with schizophrenia – a naturalistic study with quetiapine. Acta Psychiat Scand 2009; 120: 120–8. 42. Wolter A, Preuss VW, Krischke NR et al. Remission, prediction and stability of symptoms in schizophrenia: a naturalistic 12-month follow-up study. Inter J Psychiat Clin Pract 2010; 14: 160–7. 43. Wunderink L, Sytema S, Nienhuis FJ et al. Clinical recovery in first-episode psychosis. Schizophr Bull 2008. 44. Zimmermann J, Wolter A, Krischke NR et al. Response und Remission bei an Schizophrenie erkrankten Patienten. Nervenarzt 2011; 11: 1440–8.